Please assess the completion status of the following clinical trial:

Trial Title: Intrapleural Gene Transfer for Pleural Mesothelioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* evidence of progressive disease after standard first line treatment of mesothelioma; OR patient has refused standard first line treatment of mesothelioma~* evaluable disease~* No radiotherapy and/or treatment with chemotherapeutic, cytotoxic, or immunologic agents within 14 days prior to infusion of the IFN-α vector~* Must have a pleural space involved with tumor accessible for pleural catheter insertion~* FEV1\> 1 liter or 40% of predicted value~* Must have an anti-adenoviral neutralizing antibody titer equal to or less than 1:1000. This will be measured by the Penn Vector Core~Exclusion Criteria:~* Presence of HIV or Hepatitis B infection~* Use of concurrent systemic steroids, immunosuppressives, or any other medications that can directly or indirectly suppress the immune system~* Presence of any other life-threatening illness, such as unstable angina, severe oxygen dependence, significant chronic obstructive pulmonary disease (COPD), end stage liver or renal disease~* Presence of untreated brain metastases~* Prior bone marrow or stem cell transplants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Level 1 (Type: EXPERIMENTAL): None
- Dose Level 2 (Type: EXPERIMENTAL): This is a dose de escalation.

Based on this trial design, predict the completion outcome and termination type (if applicable).